Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
2.67 USD -1.11% Intraday chart for Lisata Therapeutics, Inc. -5.65% -2.20%
Apr. 17 Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer CI
Apr. 09 Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma CI

Evolution of the average Target Price on Lisata Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

cf801b492c0.yrxtHV-TsAZWOmnVdGnmMdecuJ-a2uf1UDe62dKnvcQ.kOQVKBGq-k1jUjuCPlCXHKXM98XbnaOkI0Twr6iR3rKV7VhCCKbedy5XXQ~397e7e1b5343dd142af3c091a53cdb8d

Analyst Recommendations on Lisata Therapeutics, Inc.

HC Wainwright Adjusts Lisata Therapeutics' Price Target to $15 From $6, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Caladrius Biosciences to $6 From $8, Reiterates Buy Rating MT
CALADRIUS BIOSCIENCES : Chardan Suspends Coverage on Caladrius Biosciences at Buy Rating With $6 Price Target MT
CALADRIUS BIOSCIENCES : Brookline Capital Management Adjusts Caladrius Biosciences PT to $10 From $7, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.67 USD
Average target price
14.5 USD
Spread / Average Target
+443.07%
High Price Target
15 USD
Spread / Highest target
+461.80%
Low Price Target
14 USD
Spread / Lowest Target
+424.34%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lisata Therapeutics, Inc.

HC Wainwright
Chardan
Brookline Capital Management

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. Consensus Lisata Therapeutics, Inc.